

Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Growth 2023-2029

https://marketpublishers.com/r/G53CEB218C7DEN.html

Date: March 2023 Pages: 94 Price: US\$ 3,660.00 (Single User License) ID: G53CEB218C7DEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

SGLT2 is a member of the sodium-glucose cotransporter family which are sodiumdependent glucose transport proteins. SGLT2 is the major cotransporter involved in glucose reabsorption in the kidney. The growing global type-2 diabetes population promotes the growth of SGLT2 drugs.

LPI (LP Information)' newest research report, the "Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Industry Forecast" looks at past sales and reviews total world Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors sales in 2022, providing a comprehensive analysis by region and market sector of projected Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors sales for 2023 through 2029. With Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors 2 (SGLT 2) Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors



shaping the global outlook for Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors.

The global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors players cover Eli Lilly, Janssen Pharmaceuticals, Astellas, Boehringer Ingelheim, AstraZeneca, Bristol Myers Squibb and Kotobuki Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Invokana (Canagliflozin)

Jardiance (Empagliflozin)

Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Growth 2023-2029



Farxiga/Forxiga (Dapagliflozin)

Suglat (Ipragliflozin)

Segmentation by application

Hospital

Medical Research Institute

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India



Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Eli Lilly

Janssen Pharmaceuticals

Astellas

Boehringer Ingelheim



AstraZeneca

Bristol Myers Squibb

Kotobuki Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market?

What factors are driving Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors market opportunities vary by end market size?

How does Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?



Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Annual Sales 2018-2029

2.1.2 World Current & Future Analysis for Sodium & Glucose Cotransporter 2 (SGLT2) Inhibitors by Geographic Region, 2018, 2022 & 2029

2.1.3 World Current & Future Analysis for Sodium & Glucose Cotransporter 2 (SGLT2) Inhibitors by Country/Region, 2018, 2022 & 2029

2.2 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Segment by Type

- 2.2.1 Invokana (Canagliflozin)
- 2.2.2 Jardiance (Empagliflozin)
- 2.2.3 Farxiga/Forxiga (Dapagliflozin)
- 2.2.4 Suglat (Ipragliflozin)

2.3 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type

2.3.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Type (2018-2023)

2.3.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue and Market Share by Type (2018-2023)

2.3.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sale Price by Type (2018-2023)

2.4 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Segment by Application

2.4.1 Hospital

2.4.2 Medical Research Institute

2.4.3 Other

2.5 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application



2.5.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sale Market Share by Application (2018-2023)

2.5.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue and Market Share by Application (2018-2023)

2.5.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sale Price by Application (2018-2023)

3 GLOBAL SODIUM & GLUCOSE COTRANSPORTER 2 (SGLT 2) INHIBITORS BY COMPANY

3.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Breakdown Data by Company

3.1.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Annual Sales by Company (2018-2023)

3.1.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Company (2018-2023)

3.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Annual Revenue by Company (2018-2023)

3.2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Company (2018-2023)

3.2.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share by Company (2018-2023)

3.3 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sale Price by Company

3.4 Key Manufacturers Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Location Distribution

3.4.2 Players Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Products Offered 3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR SODIUM & GLUCOSE COTRANSPORTER 2 (SGLT 2) INHIBITORS BY GEOGRAPHIC REGION

4.1 World Historic Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size



by Geographic Region (2018-2023)

4.1.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size by Country/Region (2018-2023)

4.2.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Annual Sales by Country/Region (2018-2023)

4.2.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Annual Revenue by Country/Region (2018-2023)

4.3 Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Growth

4.4 APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Growth

4.5 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Growth

4.6 Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Growth

5 AMERICAS

5.1 Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country

5.1.1 Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country (2018-2023)

5.1.2 Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country (2018-2023)

5.2 Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type5.3 Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales byApplication

5.4 United States

- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

6.1 APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Region

6.1.1 APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Region (2018-2023)

6.1.2 APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Region (2018-2023)



6.2 APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type

6.3 APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application

- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

7.1 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors by Country

7.1.1 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country (2018-2023)

7.1.2 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country (2018-2023)

7.2 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type

7.3 Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application

7.4 Germany

- 7.5 France
- 7.6 UK
- 7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors by Country

8.1.1 Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country (2018-2023)

8.1.2 Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country (2018-2023)

8.2 Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type

8.3 Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application

8.4 Egypt

8.5 South Africa



8.6 Israel8.7 Turkey8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Sodium & Glucose Cotransporter 2
(SGLT 2) Inhibitors
10.3 Manufacturing Process Analysis of Sodium & Glucose Cotransporter 2 (SGLT 2)
Inhibitors
10.4 Industry Chain Structure of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors

11 MARKETING, DISTRIBUTORS AND CUSTOMER

- 11.1 Sales Channel
- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Distributors
- 11.3 Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Customer

12 WORLD FORECAST REVIEW FOR SODIUM & GLUCOSE COTRANSPORTER 2 (SGLT 2) INHIBITORS BY GEOGRAPHIC REGION

12.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Size Forecast by Region

12.1.1 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Forecast by Region (2024-2029)

12.1.2 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Annual Revenue Forecast by Region (2024-2029)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country



12.5 Middle East & Africa Forecast by Country

12.6 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Forecast by Type 12.7 Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Eli Lilly

13.1.1 Eli Lilly Company Information

13.1.2 Eli Lilly Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolios and Specifications

13.1.3 Eli Lilly Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)

13.1.4 Eli Lilly Main Business Overview

13.1.5 Eli Lilly Latest Developments

13.2 Janssen Pharmaceuticals

13.2.1 Janssen Pharmaceuticals Company Information

13.2.2 Janssen Pharmaceuticals Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolios and Specifications

13.2.3 Janssen Pharmaceuticals Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)

13.2.4 Janssen Pharmaceuticals Main Business Overview

13.2.5 Janssen Pharmaceuticals Latest Developments

13.3 Astellas

13.3.1 Astellas Company Information

13.3.2 Astellas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolios and Specifications

13.3.3 Astellas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)

13.3.4 Astellas Main Business Overview

13.3.5 Astellas Latest Developments

13.4 Boehringer Ingelheim

13.4.1 Boehringer Ingelheim Company Information

13.4.2 Boehringer Ingelheim Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolios and Specifications

13.4.3 Boehringer Ingelheim Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 Boehringer Ingelheim Main Business Overview

13.4.5 Boehringer Ingelheim Latest Developments



13.5 AstraZeneca

13.5.1 AstraZeneca Company Information

13.5.2 AstraZeneca Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolios and Specifications

13.5.3 AstraZeneca Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales,

Revenue, Price and Gross Margin (2018-2023)

13.5.4 AstraZeneca Main Business Overview

13.5.5 AstraZeneca Latest Developments

13.6 Bristol Myers Squibb

13.6.1 Bristol Myers Squibb Company Information

13.6.2 Bristol Myers Squibb Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolios and Specifications

13.6.3 Bristol Myers Squibb Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)

13.6.4 Bristol Myers Squibb Main Business Overview

13.6.5 Bristol Myers Squibb Latest Developments

13.7 Kotobuki Pharmaceutical

13.7.1 Kotobuki Pharmaceutical Company Information

13.7.2 Kotobuki Pharmaceutical Sodium & Glucose Cotransporter 2 (SGLT 2)

Inhibitors Product Portfolios and Specifications

13.7.3 Kotobuki Pharmaceutical Sodium & Glucose Cotransporter 2 (SGLT 2)

Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)

13.7.4 Kotobuki Pharmaceutical Main Business Overview

13.7.5 Kotobuki Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION



List Of Tables

LIST OF TABLES

Table 1. Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions) Table 2. Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions) Table 3. Major Players of Invokana (Canagliflozin) Table 4. Major Players of Jardiance (Empagliflozin) Table 5. Major Players of Farxiga/Forxiga (Dapagliflozin) Table 6. Major Players of Suglat (Ipragliflozin) Table 7. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type (2018-2023) & (K Units) Table 8. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Type (2018-2023) Table 9. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Type (2018-2023) & (\$ million) Table 10. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share by Type (2018-2023) Table 11. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sale Price by Type (2018-2023) & (USD/Unit) Table 12. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application (2018-2023) & (K Units) Table 13. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Application (2018-2023) Table 14. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Application (2018-2023) Table 15. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share by Application (2018-2023) Table 16. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sale Price by Application (2018-2023) & (USD/Unit) Table 17. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Company (2018-2023) & (K Units) Table 18. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Company (2018-2023) Table 19. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Company (2018-2023) (\$ Millions) Table 20. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue



Market Share by Company (2018-2023) Table 21. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sale Price by Company (2018-2023) & (USD/Unit) Table 22. Key Manufacturers Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Producing Area Distribution and Sales Area Table 23. Players Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Products Offered Table 24. Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2018-2023) Table 25. New Products and Potential Entrants Table 26. Mergers & Acquisitions, Expansion Table 27. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Geographic Region (2018-2023) & (K Units) Table 28. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share Geographic Region (2018-2023) Table 29. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Geographic Region (2018-2023) & (\$ millions) Table 30. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share by Geographic Region (2018-2023) Table 31. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country/Region (2018-2023) & (K Units) Table 32. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Country/Region (2018-2023) Table 33. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country/Region (2018-2023) & (\$ millions) Table 34. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share by Country/Region (2018-2023) Table 35. Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country (2018-2023) & (K Units) Table 36. Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Country (2018-2023) Table 37. Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country (2018-2023) & (\$ Millions) Table 38. Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share by Country (2018-2023) Table 39. Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type (2018-2023) & (K Units) Table 40. Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application (2018-2023) & (K Units)



Table 41. APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Region (2018-2023) & (K Units) Table 42. APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Region (2018-2023) Table 43. APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Region (2018-2023) & (\$ Millions) Table 44. APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share by Region (2018-2023) Table 45. APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type (2018-2023) & (K Units) Table 46. APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application (2018-2023) & (K Units) Table 47. Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country (2018-2023) & (K Units) Table 48. Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Country (2018-2023) Table 49. Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country (2018-2023) & (\$ Millions) Table 50. Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share by Country (2018-2023) Table 51. Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type (2018-2023) & (K Units) Table 52. Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application (2018-2023) & (K Units) Table 53. Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Country (2018-2023) & (K Units) Table 54. Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Country (2018-2023) Table 55. Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue by Country (2018-2023) & (\$ Millions) Table 56. Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share by Country (2018-2023) Table 57. Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Type (2018-2023) & (K Units) Table 58. Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Application (2018-2023) & (K Units) Table 59. Key Market Drivers & Growth Opportunities of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Table 60. Key Market Challenges & Risks of Sodium & Glucose Cotransporter 2 (SGLT



2) Inhibitors

Table 61. Key Industry Trends of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Table 62. Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Raw Material Table 63. Key Suppliers of Raw Materials Table 64. Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Distributors List Table 65. Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Customer List Table 66. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Forecast by Region (2024-2029) & (K Units) Table 67. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Forecast by Region (2024-2029) & (\$ millions) Table 68. Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Forecast by Country (2024-2029) & (K Units) Table 69. Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Forecast by Country (2024-2029) & (\$ millions) Table 70. APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Forecast by Region (2024-2029) & (K Units) Table 71. APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Forecast by Region (2024-2029) & (\$ millions) Table 72. Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Forecast by Country (2024-2029) & (K Units) Table 73. Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Forecast by Country (2024-2029) & (\$ millions) Table 74. Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Forecast by Country (2024-2029) & (K Units) Table 75. Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Forecast by Country (2024-2029) & (\$ millions) Table 76. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Forecast by Type (2024-2029) & (K Units) Table 77. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Forecast by Type (2024-2029) & (\$ Millions) Table 78. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Forecast by Application (2024-2029) & (K Units) Table 79. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Forecast by Application (2024-2029) & (\$ Millions) Table 80. Eli Lilly Basic Information, Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Manufacturing Base, Sales Area and Its Competitors Table 81. Eli Lilly Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolios and Specifications



Table 82. Eli Lilly Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 83. Eli Lilly Main Business

Table 84. Eli Lilly Latest Developments

 Table 85. Janssen Pharmaceuticals Basic Information, Sodium & Glucose

Cotransporter 2 (SGLT 2) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 86. Janssen Pharmaceuticals Sodium & Glucose Cotransporter 2 (SGLT 2)Inhibitors Product Portfolios and Specifications

Table 87. Janssen Pharmaceuticals Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 88. Janssen Pharmaceuticals Main Business

Table 89. Janssen Pharmaceuticals Latest Developments

Table 90. Astellas Basic Information, Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 91. Astellas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolios and Specifications

Table 92. Astellas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales (K

Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 93. Astellas Main Business

Table 94. Astellas Latest Developments

 Table 95. Boehringer Ingelheim Basic Information, Sodium & Glucose Cotransporter 2

(SGLT 2) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 96. Boehringer Ingelheim Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolios and Specifications

Table 97. Boehringer Ingelheim Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 98. Boehringer Ingelheim Main Business

Table 99. Boehringer Ingelheim Latest Developments

Table 100. AstraZeneca Basic Information, Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 101. AstraZeneca Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolios and Specifications

Table 102. AstraZeneca Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 103. AstraZeneca Main Business

Table 104. AstraZeneca Latest Developments

Table 105. Bristol Myers Squibb Basic Information, Sodium & Glucose Cotransporter 2,



(SGLT 2) Inhibitors Manufacturing Base, Sales Area and Its Competitors Table 106. Bristol Myers Squibb Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Product Portfolios and Specifications

Table 107. Bristol Myers Squibb Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors

Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

 Table 108. Bristol Myers Squibb Main Business

Table 109. Bristol Myers Squibb Latest Developments

Table 110. Kotobuki Pharmaceutical Basic Information, Sodium & Glucose

Cotransporter 2 (SGLT 2) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 111. Kotobuki Pharmaceutical Sodium & Glucose Cotransporter 2 (SGLT 2)Inhibitors Product Portfolios and Specifications

Table 112. Kotobuki Pharmaceutical Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales (K Units), Revenue (\$ Million), Price (USD/Unit) and Gross Margin (2018-2023)

Table 113. Kotobuki Pharmaceutical Main Business

Table 114. Kotobuki Pharmaceutical Latest Developments



List Of Figures

LIST OF FIGURES

Figure 1. Picture of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Figure 2. Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Report Years Considered Figure 3. Research Objectives Figure 4. Research Methodology Figure 5. Research Process and Data Source Figure 6. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Growth Rate 2018-2029 (K Units) Figure 7. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth Rate 2018-2029 (\$ Millions) Figure 8. Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales by Region (2018, 2022 & 2029) & (\$ Millions) Figure 9. Product Picture of Invokana (Canagliflozin) Figure 10. Product Picture of Jardiance (Empagliflozin) Figure 11. Product Picture of Farxiga/Forxiga (Dapagliflozin) Figure 12. Product Picture of Suglat (Ipragliflozin) Figure 13. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Type in 2022 Figure 14. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share by Type (2018-2023) Figure 15. Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumed in Hospital Figure 16. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market: Hospital (2018-2023) & (K Units) Figure 17. Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumed in Medical **Research Institute** Figure 18. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market: Medical Research Institute (2018-2023) & (K Units) Figure 19. Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Consumed in Other Figure 20. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market: Other (2018-2023) & (K Units) Figure 21. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Application (2022) Figure 22. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share by Application in 2022



Figure 23. Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market by Company in 2022 (K Units) Figure 24. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Company in 2022 Figure 25. Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market by Company in 2022 (\$ Million) Figure 26. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share by Company in 2022 Figure 27. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Geographic Region (2018-2023) Figure 28. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share by Geographic Region in 2022 Figure 29. Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales 2018-2023 (K Units) Figure 30. Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue 2018-2023 (\$ Millions) Figure 31. APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales 2018-2023 (K Units) Figure 32. APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue 2018-2023 (\$ Millions) Figure 33. Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales 2018-2023 (K Units) Figure 34. Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue 2018-2023 (\$ Millions) Figure 35. Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales 2018-2023 (K Units) Figure 36. Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue 2018-2023 (\$ Millions) Figure 37. Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Country in 2022 Figure 38. Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share by Country in 2022 Figure 39. Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Type (2018-2023) Figure 40. Americas Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Application (2018-2023) Figure 41. United States Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions) Figure 42. Canada Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue



Growth 2018-2023 (\$ Millions) Figure 43. Mexico Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions) Figure 44. Brazil Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions) Figure 45. APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Region in 2022 Figure 46. APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share by Regions in 2022 Figure 47. APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Type (2018-2023) Figure 48. APAC Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Application (2018-2023) Figure 49. China Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions) Figure 50. Japan Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions) Figure 51. South Korea Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions) Figure 52. Southeast Asia Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions) Figure 53. India Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions) Figure 54. Australia Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions) Figure 55. China Taiwan Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions) Figure 56. Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Country in 2022 Figure 57. Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share by Country in 2022 Figure 58. Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Type (2018-2023) Figure 59. Europe Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Application (2018-2023) Figure 60. Germany Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions) Figure 61. France Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions)



Figure 62. UK Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 63. Italy Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 64. Russia Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 65. Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Country in 2022

Figure 66. Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share by Country in 2022

Figure 67. Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Type (2018-2023)

Figure 68. Middle East & Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share by Application (2018-2023)

Figure 69. Egypt Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 70. South Africa Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 71. Israel Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 72. Turkey Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 73. GCC Country Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 74. Manufacturing Cost Structure Analysis of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors in 2022

Figure 75. Manufacturing Process Analysis of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors

Figure 76. Industry Chain Structure of Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors

Figure 77. Channels of Distribution

Figure 78. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Forecast by Region (2024-2029)

Figure 79. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share Forecast by Region (2024-2029)

Figure 80. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share Forecast by Type (2024-2029)

Figure 81. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share Forecast by Type (2024-2029)



Figure 82. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Sales Market Share Forecast by Application (2024-2029) Figure 83. Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Revenue Market Share Forecast by Application (2024-2029)



I would like to order

Product name: Global Sodium & Glucose Cotransporter 2 (SGLT 2) Inhibitors Market Growth 2023-2029 Product link: <u>https://marketpublishers.com/r/G53CEB218C7DEN.html</u>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/G53CEB218C7DEN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970